United States: Medicaid Waivers In Conservative States Hold Hints For What Is To Come For Drug Manufacturers

Last Updated: December 29 2016
Article by Christian Springer and Ross Margulies

The nomination of Seema Verma by President-Elect Trump for the position of CMS Administrator sends a clear signal that the Trump Administration considers Medicaid one of its top healthcare reform priorities.  Seema Verma is the the "architect" of the Healthy Indiana Plan 2.0" waiver (HIP 2.0), a consumer-driven Medicaid expansion demonstration approved by the Obama Administration under a Section 1115 waiver.  Most recently, Verma was also involved in designing Kentucky's proposed "Kentucky HEALTH" ("HEALTH") Section 1115 waiver, which is heavily modeled after HIP 2.0.  Verma's nomination suggests that CMS, under a Trump Administration, will offer states greater flexibility in designing their Medicaid programs than was previously allowed under the Obama Administration.  Looking at the terms of the approved Indiana waiver, as well as the pending Kentucky waiver, is a helpful exercise in understanding the direction Medicaid might move over the next four years.

The analysis that follows briefly summarizes the most salient features of the HIP 2.0 and HEALTH waivers, and draws particular attention to how features of these waivers may impact the pharmaceutical industry.  In general, manufacturers should anticipate an increased number of Medicaid beneficiaries facing some sort of cost-sharing (either in the form of small co-payments, or deductibles), as well as a general push by states to negotiate new supplemental rebate agreements in exchange for preferred formulary status.  If CMS ultimately permits expanded use of "lock-out" periods for failure to comply with some aspect of the state's program (for example, failure to pay a premium), demand for free or reduced price drug will certain increase.

Overview of Healthy Indiana Plan 2.0 Waiver

The HIP 2.0 waiver provides health insurance coverage to those newly eligible individuals under the Affordable Care Act ("ACA's") Medicaid expansion.  The program is divided into two different benefit plans: "HIP Basic" and "HIP Plus."  Medicaid beneficiaries in the HIP Basic and HIP Plus plans are paired with a "POWER" account valued at $2,500, which can be used pay the required $2,500 plan deductible associated with both plans.  This POWER account operates similar to a Health Savings Account ("HSA") and is the most prominent feature of HIP 2.0.  Beneficiaries who select not to make any POWER account contributions are automatically enrolled in the HIP Basic plan; while beneficiaries who do make these contributions are enrolled in the HIP Plus plan.  HIP Basic enrollees receive a standard set of benefits and are responsible for co-pays for most services; HIP Plus enrollees receive extra benefits (like vision, dental and comprehensive drug coverage) and are not responsible for making co-payments Notably, HIP Plus members who are above 100% of the FPL and fail to make a contribution to their POWER account for 60 days are locked-out of Medicaid entirely for 6 months.  Conversely, HIP Plus members who are below 100% of the FPL are downgraded to the HIP Basic plan, but are not entirely locked out.

As alluded to previously, HIP Plus members enjoy a more generous pharmacy benefit than their Basic counterparts.  HIP Basic plan members cannot receive medications by mail order and all drugs have a 30-day supply limit.  In addition, HIP Basic members are required to make co-payments on their prescriptions ($4 for preferred drugs, $8 for non-preferred drugs).  In contrast, HIP Plus members can receive medications by mail order and enjoy a 90-day supply limit for maintenance drugs and a 30-day supply limit for non-maintenance drugs.  In addition, HIP Plus do not have any co-payments associated with prescription refills.

Overview of Kentucky Helping to Engage and Achieve Long Term Health (HEALTH) Waiver

The HEALTH waiver proposal (currently pending before CMS), if approved, would impact both Medicaid expansion beneficiaries and traditional non-disabled Medicaid beneficiaries in Kentucky.  Beneficiaries at income levels below 138% of FPL would be required, in lieu of co-payments, to pay monthly premiums on an income-based sliding scale, beginning at $1 per month and maxing out at $15 per month.  They would also be paired with two separate, but related, accounts.  The first "deductible" account is similar to an HSA and would be valued at $1,000 and could be used to pay medical expenses up to the required $1,000 plan deductible.  The second account is referred to as the "My Rewards Account."  Funds for this account are accrued by completing specified health-related community engagement activities, such as participating in community service or job training. Furthermore, at the end of the year, 50% of the remaining balance (if any) from the deductible account can be carried over to the My Rewards Account.  The My Rewards Account can be used to purchase extra benefits like dental, vision, OTC medications, and gym memberships.  The benchmark plan (the base coverage for plan offerings) would be the Kentucky State Employees Health Plan.

The HEALTH waiver is intended to familiarize members with commercial market coverage, and therefore it institutes several requirements that have parallels to commercial insurance.  For example, retroactive coverage is eliminated for newly enrolled individuals, and their benefits do not kick-in until they make their first premium payment. Failure to pay outstanding premiums for 60 days would result in disenrollment, and members could re-enroll only after they pay off the entire premium balance, the premium for the reinstatement month, and participate in a financial and health literacy program. However, members below 100% FPL who fail to pay premiums will instead make co-payments for all services. Additionally, there are member-specific open enrollment periods which would require enrollment during a set time frame, and failure to comply with annual eligibility redetermination requirements could lead to a 6-month lockout from the program.  "Able-bodied" working age adults would also be required to participate in a work activity to maintain enrollment, which includes volunteer work, employment, job searching, job training, etc.

As alluded to above, the Kentucky HEALTH Plan does include prescription drug coverage as a standard benefit, but it excludes OTC medications.  The OTC medication benefit can be purchased as an additional benefit by a plan member with funds in their My Rewards Account.

Implications for the Pharmaceutical Industry

Novel lock-out periods and elimination of retroactive coverage could inject substantial fluctuations into the demand for drugs

As states increasingly seek to introduce lock-out periods and eliminate retroactive coverage in the Medicaid program, manufacturers could an increased demand for free drugs and other related patient assistance programs as individuals are locked out of coverage.  In general, efforts to place limits or conditions on an individual's eligibility for Medicaid will inevitably create a new coverage gap in a population that has traditionally had full, if not robust, prescription drug coverage.

Models with tiered benefit plans could reduce demand for branded drugs

As described above, the HIP 2.0 waiver has a tiered benefit design (Basic v. Plus).  HIP Plus plan members enjoy, among other benefits, comprehensive drug coverage, and unlike their Basic member counterparts, they do not need to make any co-payments.  Although the co-payments that Basic members must make for their drugs are modest ($4 for preferred v. $8 for non-preferred), Medicaid beneficiaries by definition do not have much disposable income, and they are therefore much likelier to select the cheapest option possible—more often than not these options are generics.  Therefore if the tiered benefit plan is expanded to other Medicaid waivers, brand pharmaceutical companies could experience reduced demand for drugs in competitive markets.1

Increased cost-sharing and tiered benefit design may place pressure on drug companies to offer more generous Medicaid rebates

Related to the first point, the demand elasticity for drugs in the context of Medicaid patients, whom have extremely limited disposable incomes, could prove to be highly elastic. Therefore, as Medicaid beneficiaries experience greater cost-sharing at the point of care through differential co-payments, manufacturers will have a stronger incentive to offer more attractive rebates to state governments with the goal of being placed on a higher tier and thereby temper the effects of high demand elasticity.

Community-oriented features could create opportunities for pharmaceutical companies to offer innovative ways to support low-income patients

A common theme among emerging conservative waiver proposals is a need to reconnect the Medicaid beneficiary with the community around them through an interplay of incentives and penalties built into the Medicaid program.  Manufacturers could engage state governments to develop subprograms that aim to improve things like patient healthy literacy (including medication adherence), financial literacy, employment prospects, and other areas. States (and managed care organizations) may be more willing to engage in activities not traditionally considered direct health care services as they creative ways to reduce costs.

Increased waiver flexibility could open up opportunities for innovative purchasing models

The incoming Administration is likely to be much more deferential to states in reviewing waiver proposals than the Obama Administration, and may be willing to consider proposals from manufacturers that have previously proven difficult to implement without clear guidance from CMS. In recent years, CMS has attempted to provide reassurances to States and manufacturers in order to encourage the use of value-based drug purchasing. In a new Administration under Seema Verma, we may see an increased effort and willingness to lend administrative flexibility to this process to encourage greater use of these models.


1. Indeed, one study of HIP 2.0  found "a measurable impact on access to prescription drugs" with members enrolled in HIP Plus being significantly more likely to use their prescription drug benefit than members enrolled in Basic.  Importantly, the study found that "differential cost sharing for preferred and non-preferred drugs may be influencing members enrolled in Basic to select drugs from the preferred list which helps increase the use of generic prescriptions.

To view Foley Hoag's Medicaid and the Law blog please click here

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Events from this Firm
25 Oct 2017, Webinar, Boston, United States

Foley Hoag will present a 60-minute webinar on Wednesday, October 25 at 12:30 pm EDT, offering guidance for in-house counsel regarding the basics of trademark and design protection in the European Union. Attendees will learn about the opportunities and pitfalls to be on the lookout for when looking to secure, protect, and enforce an IP portfolio overseas.

1 Nov 2017, Webinar, Boston, United States

Please join Foley Hoag on Wednesday, November 1, 2017 for a webinar that covers the details of drafting an appropriate arbitration clause for your company’s commercial contracts.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.